10x GenomicsTXG
Recorded

10x Genomics 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration39 minParticipants14

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Hello, everyone. Thank you for joining us, and welcome to the 10X Genomics Third Quarter 2026 Earnings Conference Call. After today's prepared remarks, we will host a question-and-answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. I will now hand the conference over to Cassie Corneau, Senior Director and Head of Investor Relations and Strategic Finance.

Cassie CorneauSenior Director and Head of Investor Relations and Strategic Finance

Please go ahead. Thank you, and good afternoon, everyone.

Cassie CorneauSenior Director and Head of Investor Relations and Strategic Finance

Earlier today, 10X Genomics released financial results for the third quarter ended September 30, 2026. If you have not received this news release or would like to be added to the company's distribution list, please send an email to investors@10xgenomics.com. An archived webcast of this call will be available on the Investor tab of the company's website, 10xgenomics.com, for at least 45 days following this call. Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated, and you should not place undue reliance on forward-looking statements.

Cassie CorneauSenior Director and Head of Investor Relations and Strategic Finance

Additional information regarding these risks, uncertainties, and factors that could cause results to differ appears in the press release 10X Genomics issued today and in the documents and reports filed by 10X Genomics from time to time with the Securities and Exchange Commission. 10X Genomics disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. Joining the call today are Serge Saxonov, our CEO and Co-founder, and Adam Taich, our Chief Financial Officer. We will host a question-and-answer session after our prepared remarks. We ask analysts to please keep to one question so that we may accommodate everyone in the queue. With that, I will now turn the call over to Serge.

Serge SaxonovCEO and Co-founder

Thanks, Cassie, and good afternoon, everyone. Revenue for the third quarter was $151 million, up 1% year-over-year. The biggest highlight was the start of commercial shipments of Atera. Enthusiasm for the platform has continued to build, and we're incredibly excited to be putting instruments in customers' hands. The rest of the business also performed well, driven by continued strength in consumables. Adam will cover the financial results and outlook in more detail. Now, stepping back, it's worth reflecting on this remarkable point in time, as progress in AI is reshaping so much of the world. Many believe that AI's greatest promise is in accelerating science and advancing human health. We agree, and the key bottleneck is the data. Biology is incredibly complex. Capturing that complexity requires measuring biological systems at massive scale and high resolution.

Serge SaxonovCEO and Co-founder

It requires measurements of molecules, cells, and tissues across vast numbers of samples, conditions, and contexts. This is precisely why we started 10X and why we have built our single-cell and spatial technologies. Now, as biology is entering this new era of AI and data maximalism, our business is positioned incredibly well to benefit and to be the key enabler of progress going forward. The success we are seeing with Atera is a powerful demonstration of this trend. The platform delivers whole-transcriptome spatial profiling with single-cell sensitivity at high throughput. It brings together molecular, cellular, and tissue biology on a single instrument. By delivering its incredible capabilities at scale, Atera is both perfectly suited and critically necessary for this new AI-driven era of biology. The extraordinary customer demand and momentum have continued to build since our last call.

Serge SaxonovCEO and Co-founder

Our priority now is to ramp production, get instruments into customers' hands, and help ensure their success. I have said before that we expected Atera to be the biggest product introduction in our history, and what we are seeing from customers is consistent with that expectation, whether judging by their enthusiasm for the platform, by the flow of orders, or by the ambition of their plans. We are also encouraged by the strong interest in Catalyst Research Services, our internal service lab for running customer samples. In its first five months, more than 100 customers booked projects representing a wide variety of applications and use cases. We are seeing extensive demand for Atera across universities, academic medical centers, and biopharma. Customers are preparing to use the platform to generate data for AI models, whether for basic science, translational research, or drug development.

Serge SaxonovCEO and Co-founder

In addition to training AI models, customers are planning to deploy Atera across a wide range of applications and fields, including population-scale studies, cell and tissue atlasing, studies of disease mechanisms, and biomarker discovery. Nearly all of the world's top 20 biopharma companies have now purchased Atera systems or services through Catalyst. As we mentioned previously, many pharmaceutical companies expect that spatial biology will fundamentally change how they approach drug discovery and development. We are hearing about applications across the entire drug development continuum, from finding therapeutic targets to understanding mechanisms of action, to assessing safety, to predicting response in patients. For example, we now have a growing arsenal of revolutionary medicines for treating cancer. The critical challenge is that most patients develop resistance, and the mechanisms are not well understood.

Serge SaxonovCEO and Co-founder

Many leading researchers are now planning to use Atera to address this challenge, because Atera can provide an unparalleled view of the underlying cancer biology and of on-treatment effects. We built Atera as a long-duration, upgradeable platform to keep expanding what is possible in spatial biology. Our roadmap includes onboard slide preparation automation to enable true sample-in, data-out capability. It also includes RNA protein multiomics and base-by-base sequencing for in situ mutation detection. Together, these capabilities will enable customers to answer an even broader range of biological questions. Turning to single cell. Our customers continue to adopt our platforms for larger, more ambitious studies. Flex Apex is enabling a new generation of this work, especially in biopharma and translational research. Our recently introduced whole blood workflows are bringing single cell into applications that would previously have been inconceivable.

Serge SaxonovCEO and Co-founder

Customers have shared enthusiasm for their ability to access troves of archival blood samples for retrospective single-cell data generation. For prospective studies, the workflow stabilizes samples and simplifies processing at the point of collection, enabling use across a variety of clinical collection settings while dramatically reducing sample variability. Ultimately, these improvements enable more complete and consistent datasets that are critical for AI and for clinically related applications. Our single-cell solutions have long been at the epicenter of the perturbation experiments that are now fueling AI biology models. Furthermore, we are now seeing increasing demand for multimodal solutions, driven by the value of measuring more biology from the same cell. Lately, we are seeing customers build up their infrastructure, investing in automation to expand the scale of these experiments. Our new Flex Apex CRISPR workflow builds on the scalability, robustness, and sensitivity of Flex Apex for perturbation studies.

Serge SaxonovCEO and Co-founder

Combined with our Proteintech Genomics panels, the largest single-cell protein panels available, researchers get the richest data per cell for model development. Our newest GEM-X Multiome configuration captures gene expression alongside the regulatory elements that control it. Taken together, we believe our menu of multimodal solutions delivers the best approach for generating valuable mechanistic data critical for drug target discovery and predictive models of biology. As the scale of data enabled by these products grows exponentially, analysis can become an even greater bottleneck. We see that as both a challenge and an opportunity. With that in mind, this quarter, we announced Sentira, our new cloud analysis platform. Sentira is designed to help customers turn large, complex biological data into experimental conclusions using agentic AI, all in a seamless, integrated experience.

Serge SaxonovCEO and Co-founder

Researchers can explore their results and iterate rapidly without having to build or manage the underlying computing infrastructure. We have announced the initial capabilities of the platform with a lot more to come in the future. Sentira Spatial uses NVIDIA-accelerated computing to reduce processing of Atera and Xenium data from hours to minutes. Sentira Single Cell brings agentic analysis to Chromium data, powered by Anthropic's Claude. Researchers can ask questions in natural language, review proposed analyses, and examine the methods and code behind the results in an editable notebook. Together, these capabilities give more scientists the computational power and analytical tools to turn increasingly complex datasets into biological understanding. As we have said, in addition to being an accelerator of data analysis, AI represents a structural tailwind for the demand for our products.

Serge SaxonovCEO and Co-founder

It is still very early days, but the effects of AI demand are being felt across many areas of our business. Today, most significant biological data generation efforts are conceived, at least in part, with the goal of training AI models. When researchers set out to build AI models of biology, they usually think in terms of multiomics, single cell, and spatial, which usually means our technologies. This is not surprising, because as I mentioned earlier, we built our technologies precisely to measure biological systems comprehensively at massive scale and high resolution. Across different segments, thought leaders are converging on the idea that we need large-scale data collection on an industrial scale. We have previously talked about some of the projects that have been publicly announced, such as the ones from Cancer Research Institute, Arc Institute, and CZI Biohub. These efforts have all been progressing and scaling up.

Serge SaxonovCEO and Co-founder

For example, recently, Biohub has been outlining its ambitions toward profiling hundreds of billions of cells to build predictive AI models of life. At the same time, governments across the world are looking to invest in sovereign AI capabilities in healthcare and biology. There is often a strong case to be made for training models based on the unique samples and profiles of local populations. These plans naturally translate into mandates to collect multi-omics single cell and spatial data. We believe these priorities could support programs to generate large biological datasets and models around the world. In biopharma, there continues to be rapid growth in AI-focused investments. Much of the initial AI investment has focused on chemistry, on designing and making molecules.

Serge SaxonovCEO and Co-founder

As we have noted in the past, we believe the next arguably larger opportunity lies in understanding the biology, identifying new therapeutic targets, and predicting how patients will respond to treatment. This requires a much deeper view of cells and tissues, and that is precisely the information our technologies enable customers to generate. We're seeing similar momentum among tech bio companies, where we are the predominant vendor of choice for single-cell and spatial data generation. This category is expanding beyond drug development companies to include diagnostics companies looking to use their large collections of patient samples to generate training data for AI models. While it's still very early, these developments strengthen our conviction that we are at the beginning of an exponential trend in the scale of AI-driven data generation. Finally, we're continuing to make progress with our clinical strategy.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day